Journal article Open Access

The use of amyloid imaging in clinical praxis: a critical review

Nordberg, Agneta


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">PET </subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Amyloid imaging</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Alzheimer’s disease</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Mild cognitive impairment</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">11C-Pittsburgh compound B</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">18F-florbetapir</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Clinical praxis</subfield>
  </datafield>
  <controlfield tag="005">20190410034009.0</controlfield>
  <controlfield tag="001">16654</controlfield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">398284</subfield>
    <subfield code="z">md5:5734a9766a96efb35e8f748f555edf2a</subfield>
    <subfield code="u">https://zenodo.org/record/16654/files/Nordberg_ClinTranslImaging_2015-P12b.pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2015-02-12</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">user-inmind</subfield>
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-ecfunded</subfield>
    <subfield code="o">oai:zenodo.org:16654</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="c">7-11</subfield>
    <subfield code="n">1</subfield>
    <subfield code="p">Clinical and Translational Imaging </subfield>
    <subfield code="v">3</subfield>
    <subfield code="y">2015</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Department of NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Novum, 141 57, Huddinge, Sweden and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden</subfield>
    <subfield code="a">Nordberg, Agneta</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">The use of amyloid imaging in clinical praxis: a critical review</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-inmind</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-ecfunded</subfield>
  </datafield>
  <datafield tag="536" ind1=" " ind2=" ">
    <subfield code="c">278850</subfield>
    <subfield code="a">Imaging of Neuroinflammation in Neurodegenerative Diseases</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">http://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer (AD) brain using positron emission tomography (PET). Three tracers (florbetapir, flutemetamol, florbetaben) have been approved by FDA and EMA for use in clinical assessment of memory impairment to exclude AD. The use of amyloid PET imaging is considered to be appropriate in patients with persistent and progressive unexplained mild cognitive impairment (MCI), in patients with established dementia with atypical clinical course or aetiology and in young patients with atypical-onset dementia. The focus of amyloid PET has so far been to understand the time course of amyloid plaque levels in AD and to use amyloid PET to discriminate between AD and patient with mild cognitive impairment (MCI) who will most likely or less likely convert to AD, respectively, at clinical follow-up. Very few studies have so far directly tested the added value of amyloid imaging as biomarker in diagnostic procedure and patient management in a clinical context. The present study reviews studies describing the possible role of PET amyloid imaging in excluding AD as well as strengthen the diagnosis of AD and detecting prodromal AD. Some studies report as a change in diagnosis following amyloid PET imaging and in therapeutic management and planning for the future for the patient and their family. Future clinical studies are needed to evaluate the appropriate clinical use of amyloid PET imaging in relation to cerebral glucose PET imaging, and CSF biomarkers.&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1007/s40336-015-0100-8</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
</record>
13
23
views
downloads
Views 13
Downloads 23
Data volume 9.2 MB
Unique views 13
Unique downloads 23

Share

Cite as